When we tested myeloid differentiation markers (CD38 and CD11b) or hemopoietic stem/progenitor cells marker (CD34) in the blasts of AML patients, we did not find any differences between untreated or TIMP-1 treated AML samples (data not shown). Here, CD38 is linked to acute myeloid leukemia.